<DOC>
	<DOCNO>NCT02414776</DOCNO>
	<brief_summary>To determine safety tolerability orally administer hydroxychloroquine hormonal therapy . To assess response rate hydroxychloroquine combination hormonal therapy .</brief_summary>
	<brief_title>Hydroxychloroquine Metastatic Estrogen Receptor-Positive Breast Cancer Progressing Hormonal Therapy</brief_title>
	<detailed_description>To determine number patient adverse effect To assess clinical response combination</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>1 . Patients ≥ 18 year age histologically confirm , metastatic ER + breast cancer clinical progression disease ( include radiographically stable disease least 50 % increment elevate tumor marker two measurement least 2 week apart ( particular tumor marker use disease status assessment study ) current hormonal therapy PFS least 3 month . 2 . Karnofsky Performance Status ( KPS ) ≥70 % life expectancy &gt; 3 month . 3 . Participants must least one target visceral lesion allow evaluation tumor response case boneonly metastasis , patient need positive imaging study bone scan , magnetic resonance imaging ( MRI ) positron emission tomographycomputed tomography ( PETCT ) CT , elevate tumor marker least twice high upper limit . 4 . Absolute neutrophil count &gt; 1500 mm3 , platelet count ≥ 80×109 L , hemoglobin ≥ 8.5 g/dL 5 . Creatinine clearance ≥ 30 mL/min , total bilirubin ≤ 2 mg/dL , AST/ALT ≤ 3 time upper limit normal range 6 . No remain grade 2 high toxicity prior cancer therapy unless judge clinically insignificant Principal Investigator 7 . At least two ( 2 ) week prior major surgery 8 . Willingness provide permission biopsy one lesion applicable study ( All patient encourage posttherapy biopsy upon progression disease , optional ) well blood sample pertinent laboratory study 9 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable nonhormonal contraceptive method ( abstinence , double barrier method ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial 1 . On combination hormonal therapy everolimus investigational agent 2 . Patients symptomatic untreated brain metastasis leptomeningeal metastasis treat still symptomatic require use steroid 18Jul2014 Protocol v3 : ABC 01 AntiAutophagy Met Breast Cancer Page 4 16 3 . Lymphangitic carcinomatosis involve ≥ 50 % lung ; evidence metastases involve one third liver sonogram compute tomography 4 . Lactating female 5 . Uncontrolled cardiac disease , congestive heart failure , angina hypertension 6 . Myocardial infarction unstable angina within 2 month treatment 7 . Known human immunodeficiency virus ( HIV ) infection chronic active Hepatitis B C ( patient NOT require test presence virus prior therapy protocol ) 8 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 9 . Serious nonhealing wound , ulcer , bone fracture 10 . Concurrent psychiatric illness/social situation would limit safety compliance study requirement 11 . Inability complete inform consent process adhere protocol treatment plan followup requirement 12 . Currently receive investigational therapeutic agent 13 . Patients know glucose6phosphate dehydrogenase deficiency , porphyria , cirrhosis condition potential significant know risk 14 . Patients history retinal damage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>